Mayo Clinic and Thermo Fisher Scientific have launched Precure, a new company designed to build a population-scale multi-omics biomedical dataset. Mayo Clinic holds a majority stake, while Thermo Fisher provides proteomics and mass spectrometry expertise. The venture builds on Mayo Clinic's Precure Research initiative launched in July 2026 and a 100,000-person prospective study funded by Regeneron Pharmaceuticals to identify early signs of disease before symptoms appear.
Precure company formation
- ▪Mayo Clinic and Thermo Fisher Scientific founded Precure, a biomedical database company, which Mayo Clinic unveiled in September 2026.
- ▪Mayo Clinic is the majority owner of Precure, while Thermo Fisher Scientific holds a minority ownership stake in the newly formed company.
- ▪Precure aims to generate population-scale molecular data to support the development of new diagnostics, therapies, and other healthcare products.
Multi-omics biomedical dataset creation
- ▪Precure plans to link longitudinal clinical information collected over several years to data generated from biospecimens using artificial intelligence and large-scale data analytics.
- ▪Precure plans to build a biomedical dataset using molecular data generated from one million biospecimens, clinical information, and other resources.
Mayo Clinic Precure Research initiative
- ▪The Precure Research initiative analyzes data on genes, proteins, metabolites, clinical records, wearable devices, and environmental exposures to detect early physiological changes.
- ▪Mayo Clinic launched the investigator-led Precure Research initiative in July 2026 to identify and understand early biological signals of disease before clinical symptoms appear.
Thermo Fisher partnership role
- ▪Thermo Fisher Scientific will provide proteomics and mass spectrometry expertise and products to Precure to support the development of its multi-omics dataset.
- ▪Mayo Clinic and Thermo Fisher Scientific previously partnered in 2021 to accelerate the clinical validation of next-generation sequencing, mass spectrometry, and immunology diagnostic tools.
Precure prospective study enrollment
- ▪Mayo Clinic initiated the Precure prospective study in January 2026, planning to enroll up to 100,000 participants to test biospecimens like blood, urine, saliva, and stool.
- ▪Participants in the Precure prospective study will provide voice recordings and complete surveys alongside biospecimen testing.
- ▪The Precure prospective study is funded by drugmaker Regeneron Pharmaceuticals, with Mayo Clinic allocating up to five years to build the comprehensive dataset.
Debatable claims
- ▪Mayo Clinic should not commercialize patient data through private joint ventures
- ▪Drugmakers should not fund population-scale medical research databases
Story comments
Loading comments…